Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Citi bullish on BeiGene's U.S. Brukinsa launch

Published 2023-07-17, 01:36 p/m
© Reuters.
BGNE
-

Citi started BeiGene (NASDAQ:BGNE) with a Buy rating and $275 price target in a note Monday, based on the firm's bullish view of the U.S. Brukinsa launch.

Analysts told investors in a note that detailed CLL survey work supports their view of BeiGene's flagship asset, Brukinsa.

"Our detailed survey of 85 U.S. hematologists/oncologists suggests BeiGene's flagship asset Brukinsa is positioned to become the favored BTK inhibitor for CLL patients starting first-line therapy," wrote the analysts.

"We project the global annual BTKi market will grow from its ~$7B revenue base in 2022 to ~$12B by 2028, of which, we see Brukinsa generating 2028 global sales of ~$4B (vs. consensus ~$3B)," they added.

In addition, Citi sees the successful execution of the U.S. launch of Brukinsa elevating BeiGene's perception as a major global biopharma player as the company diversifies revenues geographically.

"Beyond Brukinsa, BeiGene has established leading commercial capabilities in China, evidenced by tislelizumab's rapid rise to market share leadership within the China PD-(L)1 class," the analysts added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.